PRME
HEALTHCAREPrime Medicine Inc
Live · NASDAQ · May 9, Close
What's Moving PRME Today?
No stock-specific AI insight has been generated for PRME yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.41
Fundamentals
Trading
PRME News
21 articles- Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·May 7, 2026
- Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss EstimatesYahoo Finance·May 7, 2026
- Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 7, 2026
- Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial OfficerYahoo Finance·Apr 23, 2026
- Prime Medicine Appoints Svetlana Makhni as Chief Financial OfficerYahoo Finance·Apr 16, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
- Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash RunwayYahoo Finance·Mar 8, 2026
- Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 3, 2026
- Prime Medicine Reports Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 3, 2026
- Prime Medicine to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy CompanyYahoo Finance·Feb 18, 2026
- Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Feb 11, 2026
- Favourable Signals For Prime Medicine: Numerous Insiders Acquired StockYahoo Finance·Jan 27, 2026
- Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 7, 2026
- LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung DiseasesYahoo Finance·Dec 31, 2025
- Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 DataYahoo Finance·Dec 31, 2025
- Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous DiseaseYahoo Finance·Dec 7, 2025
- Prime Medicine to Present at 8th Annual Evercore Healthcare ConferenceYahoo Finance·Nov 25, 2025
- Prime Medicine to Present at Jefferies Global Healthcare ConferenceYahoo Finance·Nov 11, 2025
- CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Nov 7, 2025
All 21 articles loaded
Price Data
52-Week Range
$3.41
Fundamentals
Trading
About Prime Medicine Inc
Prime Medicine, Inc. is a forefront biotechnology company innovating in genetic medicine through its proprietary Prime Editing technology, which allows for precise DNA modifications. With a robust pipeline focused on addressing severe diseases, including genetic disorders and various cancers, the company is well-positioned to tackle substantial unmet medical needs. Supported by strong intellectual property assets, Prime Medicine is poised to be a significant contributor to the biopharmaceutical industry, offering promising growth opportunities and transformative solutions that could redefine treatment paradigms.